Hsbc Holdings PLC Sells 53,542 Shares of Halozyme Therapeutics, Inc. $HALO

Hsbc Holdings PLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 65.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,781 shares of the biopharmaceutical company’s stock after selling 53,542 shares during the quarter. Hsbc Holdings PLC’s holdings in Halozyme Therapeutics were worth $1,854,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Empowered Funds LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $755,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics during the 1st quarter valued at $195,000. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Baird Financial Group Inc. lifted its position in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth $620,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,102 shares of company stock worth $5,205,798 in the last ninety days. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

HALO has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Halozyme Therapeutics Price Performance

HALO opened at $81.93 on Monday. The company has a fifty day moving average price of $73.08 and a 200-day moving average price of $70.58. The firm has a market capitalization of $9.72 billion, a P/E ratio of 29.47, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics, Inc. has a one year low of $57.67 and a one year high of $82.99.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the prior year, the firm posted $1.11 earnings per share. The business’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.